Project Details


Industrial postdoc with Novo Nordisk:
The treatment and prevention of diseases within the metabolic syndrome is a key focus area for Novo Nordisk. The objective of this project is to develop analytical methods for identifying diagnostic, prognostic and predictive image-based biomarkers for diseases within this complex cluster of conditions. This will increase the understanding of the diseases and support the development of
personalized treatment. The project will focus on obesity and non-alcoholic steatohepatitis (NASH), and the effect of treatment with semaglutide, a glucagon-like peptide-1 receptor agonist (GLP1-RA) developed by Novo Nordisk A/S. For both disease areas, there is a need for improved diagnostic,
prognostic, and predictive biomarkers. In this project, we will go beyond current summary measures and instead apply deep learning methodology to the raw images to identify novel and interpretable imaging biomarkers, as we expect that complex patterns in medical images can be unveiled using deep learning methods.
Effective start/end date15/10/202214/10/2025

Collaborative partners